{"id":"W4386074702","doi":"10.1097/01.hs9.0000971004.26914.cb","title":"P1027: UPDATED DURABILITY OF RESPONSE AND SAFETY IN MANIFEST ARM 3: PELABRESIB (CPI-0610) COMBINED WITH RUXOLITINIB FOR JAK INHIBITOR TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Ruxolitinib; Myelofibrosis; Internal medicine; Discontinuation; Phases of clinical research; Clinical endpoint; Gastroenterology; Oncology; Bone marrow; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002451084,0.0004048634,0.0008092673,0.0001196313,0.0001204329,0.00002059612,0.00005575313,0.0001340041,0.0002080803],"category_scores_gemma":[0.0001194247,0.0002631165,0.00008851962,0.0005198572,0.0001689476,0.0001058381,0.00003863361,0.0001050785,0.00001604619],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002701976,"about_ca_system_score_gemma":0.0002200779,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001324024,"about_ca_topic_score_gemma":0.0006513128,"domain_scores_codex":[0.9979104,0.0001451242,0.0005295363,0.0006241206,0.0003438291,0.0004469534],"domain_scores_gemma":[0.9982225,0.0006318826,0.0001925571,0.0004403648,0.0002895685,0.0002231337],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.06855091,0.002893013,0.9237134,0.00033699,0.0003096364,0.00008417242,0.0008722204,0.00001122667,0.000402252,0.000261532,0.0005400909,0.002024497],"study_design_scores_gemma":[0.03054612,0.01581402,0.9389118,0.0006126527,0.0002352708,0.00001351108,0.000725039,0.0000868588,0.01182296,0.00005204246,0.0009140368,0.0002656968],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9945327,0.00006485655,0.000004501986,0.001107321,0.000037946,0.003261402,0.0004708402,0.00009066386,0.0004297459],"genre_scores_gemma":[0.9965501,0.00006477155,0.001081738,0.00007121772,0.00003080164,0.0006307629,0.0006926198,0.00006201811,0.0008159032],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0380048,"threshold_uncertainty_score":0.9999821,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.012602810886682,"score_gpt":0.2505186048097666,"score_spread":0.2379157939230846,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}